Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.
about
Aberrant Lipid Metabolism Promotes Prostate Cancer: Role in Cell Survival under Hypoxia and Extracellular Vesicles BiogenesisMechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate CancerGenomic and Histopathological Tissue Biomarkers That Predict Radiotherapy Response in Localised Prostate CancerCancer-stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasisThe clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunitiesInfluence of hypoxia and irradiation on osteopontin expression in head and neck cancer and glioblastoma cell lines.Dynamic oxygen challenge evaluated by NMR T1 and T2*--insights into tumor oxygenationEndothelial Caveolin-1 regulates the radiation response of epithelial prostate tumors.Quantitative T1 mapping under precisely controlled graded hyperoxia at 7T.Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cellsTargeting hypoxic tumour cells to overcome metastasis.Radiation therapy in prostate cancer: a risk-adapted strategy.Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cellsHigh-density tissue microarrays from prostate needle biopsies.The role of hypoxia-inducible factor 1α in determining the properties of castrate-resistant prostate cancers.Radiosensitization in prostate cancer: mechanisms and targetsBiphasic regulation of autophagy by miR-96 in prostate cancer cells under hypoxia.Metabolic imbalance and prostate cancer progression.A tissue biomarker-based model that identifies patients with a high risk of distant metastasis and differential survival by length of androgen deprivation therapy in RTOG protocol 92-02.Impact of hypoxia on the metastatic potential of human prostate cancer cells.Multi-transcript profiling in archival diagnostic prostate cancer needle biopsies to evaluate biomarkers in non-surgically treated men.Prognostic role of vascular endothelial growth factor in prostate cancer: a systematic review and meta-analysis.Decreased expression of lysophosphatidylcholine (16:0/OH) in high resolution imaging mass spectrometry independently predicts biochemical recurrence after surgical treatment for prostate cancer.A novel HIF-1α-integrin-linked kinase regulatory loop that facilitates hypoxia-induced HIF-1α expression and epithelial-mesenchymal transition in cancer cellsTissue biomarkers for prostate cancer radiation therapy.Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response.Does salvage radiation therapy change the biology of recurrent prostate cancer based on PSA doubling times? Results from the SEARCH database.HIF-1α pathway: role, regulation and intervention for cancer therapy.Perioperative changes in osteopontin and TGFβ1 plasma levels and their prognostic impact for radiotherapy in head and neck cancer.Genetic polymorphisms in key hypoxia-regulated downstream molecules and phenotypic correlation in prostate cancer.Oxygen-Enhanced MRI Accurately Identifies, Quantifies, and Maps Tumor Hypoxia in Preclinical Cancer ModelsVascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610.Inhibition of HIF-1alpha by the anticancer drug TAS106 enhances X-ray-induced apoptosis in vitro and in vivo.Correlation between tumor growth delay and expression of cancer and host VEGF, VEGFR2, and osteopontin in response to radiotherapy.An improved method for constructing tissue microarrays from prostate needle biopsy specimens.Biologically conformal treatment: biomarkers and functional imaging in radiation oncology.The importance of protein kinase A in prostate cancer: relationship to patient outcome in Radiation Therapy Oncology Group trial 92-02.AMP-activated protein kinase promotes human prostate cancer cell growth and survival.Effect of the number of biopsy cores on prostate cancer detection and staging.Bringing the heavy: carbon ion therapy in the radiobiological and clinical context.
P2860
Q26744233-E14D7B98-88DC-4EEC-B722-ED0D17E84E99Q26766638-5ACF1510-F284-498C-9905-536C8D0F2F64Q26778586-5ED7E552-DCBE-4567-A424-8976A1BCC17CQ26866144-97568BA8-7F7E-4EA3-B0E4-CD5F28722034Q27025579-1F386778-085C-4D45-8657-FCE97A31E356Q30316284-713C4C97-D4D4-47E2-9A9C-C9F36C51B743Q30377914-E88E1DA1-C49C-4734-B3F0-83C5089EC7CEQ30652492-A649BACD-F8B8-4BA5-8634-A9E7388F0180Q31111195-D5605C95-C1C2-4B4E-A26B-287C29C0B1B5Q33402834-E60434F0-75DD-43A4-89C6-E9FCC37792D1Q34086671-D2A766AE-21B5-41AE-92EC-D1EB0131E0FFQ34111590-2AC7F0E5-C6D8-4062-A745-CD28BD106786Q34173692-520E26E0-EB08-41FF-AFE7-0DB1D5940B73Q34410083-B8F272EA-E6B3-4AEF-BDCA-9C932DF7B2D0Q34559250-7F78E4D3-8B3A-4F70-84FE-F3E55F796D94Q34563981-75FC80D0-674C-4BF4-AC27-0F5C2DDF2349Q34619280-D72A0567-24A2-43D6-B22E-47EB58DD16B3Q34794028-619B0B0D-D504-4BAD-A946-63320F1EE6B5Q34986428-C6EEB2D3-F0AA-4307-B070-95BADD5DB376Q35186588-21B4EF3B-626F-4683-9BF6-A8C96E904268Q35256915-CA0853D5-74DD-4EC9-8E98-00BE70AE8422Q35480244-69424C20-842E-498D-8F20-D2FED4F0F922Q35762498-70388318-0139-443E-A5AE-E3DD4A2A0394Q35781567-D33F95CF-C758-43E5-AF76-4878A0D069EAQ36141341-47200B28-583E-46AB-A6DD-5C4E1BDD30ECQ36184227-D4EDEF92-C04F-422B-BCD6-33A7ACFB8500Q36199750-3E5A3AEA-57F1-49CE-BD2F-AA0001F8B6C1Q36238647-A54F6ED6-8BF4-40C7-A50F-DD9C75A1C3C7Q36238876-5FB04950-E465-4B8F-853E-63F276216CD2Q36265638-9BAE7B83-CF74-485E-986F-BFB58C33CEFBQ36591139-F1CFBC39-72FB-409D-8C8D-4A042F05E8DBQ36843454-1B1518DE-25AF-4ABF-BC2F-B06695C1394DQ36965074-6539ECA7-D00A-4A31-91B7-A2A4E611C541Q36978021-83173DF4-0C53-4590-8630-0A6527E97571Q37260048-9C4FEF77-1FF8-43EF-8D0F-4DCDE3E07F86Q37298667-CF46C2C0-A649-4AF0-A69B-1B1CC8D5C704Q37389907-223E9254-34D0-4A43-973B-1644D2E15E70Q37415957-8559A707-9AE1-4775-B683-2395CCAD494AQ37707378-54243F2D-DD61-40FA-9D33-C9765219AF7FQ37727823-C85AC744-DBB6-4C93-BF0C-240E29AD6F95
P2860
Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Intrinsic markers of tumour hy ...... and one surgical cohort study.
@en
Intrinsic markers of tumour hy ...... and one surgical cohort study.
@nl
type
label
Intrinsic markers of tumour hy ...... and one surgical cohort study.
@en
Intrinsic markers of tumour hy ...... and one surgical cohort study.
@nl
prefLabel
Intrinsic markers of tumour hy ...... and one surgical cohort study.
@en
Intrinsic markers of tumour hy ...... and one surgical cohort study.
@nl
P2093
P1433
P1476
Intrinsic markers of tumour hy ...... and one surgical cohort study.
@en
P2093
Alan Horwich
Andrew R Norman
Catherine M Corbishley
Chris Parker
Colin Cooper
David Dearnaley
Jaclyn Bartlett
Michael Borre
Robert Huddart
Roy Vergis
P304
P356
10.1016/S1470-2045(08)70076-7
P407
P577
2008-03-17T00:00:00Z